[Dabrafenib (high-grade malignant glioma in paediatric patients aged 1 year and older, in combination with trametinib) – Assessment according to §35a SGB V (1), Sentence 11]
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018013478
German
Original Title:
Dabrafenib und Trametinib (malignes Gliom)
Details
Project Status:
Completed
URL for project:
https://www.iqwig.de/projekte/g24-07.html
Year Published:
2024
URL for published report:
https://www.iqwig.de/download/g24-07-und-g24-08_dabrafenib-und-trametinib_bewertung-35a-absatz-1-satz-11-sgb-v_v1-0.pdf
English language abstract:
There is no English language summary available
Publication Type:
Full HTA
Country:
Germany
MeSH Terms
- Glioma
- Brain Neoplasms
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Antibodies, Monoclonal
- Child
- Adolescent
Keywords
- Dabrafenib
- Trametinib
- Glioma
- Child
- Adolescent
- Health Care Costs
- Epidemiology
Contact
Organisation Name:
Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address:
IQWiG, Siegburger Str. 237, 50679 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email:
berichte@iqwig.de
Copyright:
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.